201 related articles for article (PubMed ID: 32185582)
1. Characterization of PD-L1 binding sites by a combined FMO/GRID-DRY approach.
Paciotti R; Agamennone M; Coletti C; Storchi L
J Comput Aided Mol Des; 2020 Aug; 34(8):897-914. PubMed ID: 32185582
[TBL] [Abstract][Full Text] [Related]
2. Investigation of protein-protein interactions and hot spot region between PD-1 and PD-L1 by fragment molecular orbital method.
Lim H; Chun J; Jin X; Kim J; Yoon J; No KT
Sci Rep; 2019 Nov; 9(1):16727. PubMed ID: 31723178
[TBL] [Abstract][Full Text] [Related]
3. Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective.
Shi D; Zhou S; Liu X; Zhao C; Liu H; Yao X
Biochim Biophys Acta Gen Subj; 2018 Mar; 1862(3):576-588. PubMed ID: 29203283
[TBL] [Abstract][Full Text] [Related]
4. Preparation of Biphenyl-Conjugated Bromotyrosine for Inhibition of PD-1/PD-L1 Immune Checkpoint Interactions.
Kim EH; Kawamoto M; Dharmatti R; Kobatake E; Ito Y; Miyatake H
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32455628
[TBL] [Abstract][Full Text] [Related]
5. Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2.
Zak KM; Grudnik P; Magiera K; Dömling A; Dubin G; Holak TA
Structure; 2017 Aug; 25(8):1163-1174. PubMed ID: 28768162
[TBL] [Abstract][Full Text] [Related]
6. Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors.
Almahmoud S; Zhong HA
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546905
[TBL] [Abstract][Full Text] [Related]
7. Identification of a hotspot on PD-L1 for pH-dependent binding by monoclonal antibodies for tumor therapy.
Liu H; Bi X; Zhou Y; Shi R; Yao S; Qi J; Feng H; Feng M; Yan J; Tan S
Signal Transduct Target Ther; 2020 Aug; 5(1):158. PubMed ID: 32839442
[No Abstract] [Full Text] [Related]
8. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1).
Zak KM; Grudnik P; Guzik K; Zieba BJ; Musielak B; Dömling A; Dubin G; Holak TA
Oncotarget; 2016 May; 7(21):30323-35. PubMed ID: 27083005
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the checkpoint PD-1 by its ligand PD-L1 and the immuno-oncological drugs pembrolizumab and nivolumab.
Tavares ABMLA; Lima Neto JX; Fulco UL; Albuquerque EL
Phys Chem Chem Phys; 2021 Sep; 23(37):21207-21217. PubMed ID: 34533552
[TBL] [Abstract][Full Text] [Related]
10. C2-Symmetrical Terphenyl Derivatives as Small Molecule Inhibitors of Programmed Cell Death 1/Programmed Death Ligand 1 Protein-Protein Interaction.
Klimek J; Kruc O; Ceklarz J; Kamińska B; Musielak B; van der Straat R; Dӧmling A; Holak TA; Muszak D; Kalinowska-Tłuścik J; Skalniak Ł; Surmiak E
Molecules; 2024 Jun; 29(11):. PubMed ID: 38893521
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
[TBL] [Abstract][Full Text] [Related]
12. Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1.
Guzik K; Zak KM; Grudnik P; Magiera K; Musielak B; Törner R; Skalniak L; Dömling A; Dubin G; Holak TA
J Med Chem; 2017 Jul; 60(13):5857-5867. PubMed ID: 28613862
[TBL] [Abstract][Full Text] [Related]
13. The Stone Guest: How Does pH Affect Binding Properties of PD-1/PD-L1 Inhibitors?
Riccio A; Coletti A; Dolciami D; Mammoli A; Cerra B; Moretti S; Gioiello A; Ferlin S; Puxeddu E; Macchiarulo A
ChemMedChem; 2021 Feb; 16(3):568-577. PubMed ID: 33085193
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Programmed Death Receptor-1/Programmed Death Ligand-1 Interactions by Ginsenoside Metabolites.
Yim NH; Kim YS; Chung HS
Molecules; 2020 Apr; 25(9):. PubMed ID: 32365500
[TBL] [Abstract][Full Text] [Related]
15. Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.
Zak KM; Kitel R; Przetocka S; Golik P; Guzik K; Musielak B; Dömling A; Dubin G; Holak TA
Structure; 2015 Dec; 23(12):2341-2348. PubMed ID: 26602187
[TBL] [Abstract][Full Text] [Related]
16. Molecular dynamics of the immune checkpoint programmed cell death protein I, PD-1: conformational changes of the BC-loop upon binding of the ligand PD-L1 and the monoclonal antibody nivolumab.
Roither B; Oostenbrink C; Schreiner W
BMC Bioinformatics; 2020 Dec; 21(Suppl 17):557. PubMed ID: 33308148
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
[TBL] [Abstract][Full Text] [Related]
18. Kaempferol and Its Glycoside, Kaempferol 7-O-Rhamnoside, Inhibit PD-1/PD-L1 Interaction In Vitro.
Kim JH; Kim YS; Choi JG; Li W; Lee EJ; Park JW; Song J; Chung HS
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32375257
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint.
Zhu P; Zhang J; Yang Y; Wang L; Zhou J; Zhang H
Mol Divers; 2022 Feb; 26(1):245-264. PubMed ID: 33786726
[TBL] [Abstract][Full Text] [Related]
20. Novel Small Molecule Inhibitors of Programmed Cell Death (PD)-1, and its Ligand, PD-L1 in Cancer Immunotherapy: A Review Update of Patent Literature.
Kopalli SR; Kang TB; Lee KH; Koppula S
Recent Pat Anticancer Drug Discov; 2019; 14(2):100-112. PubMed ID: 30370857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
